<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased levels of an unidentified peak have been found in cerebrospinal fluid (CSF) from patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> or vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> compared to the level in healthy controls using proton magnetic resonance spectroscopy </plain></SENT>
<SENT sid="1" pm="."><plain>No increase was found in patients with <z:hpo ids='HP_0007354'>amyotrophic lateral sclerosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Reexamination of spectra from a study published previously (GÃ¥rseth et al </plain></SENT>
<SENT sid="3" pm="."><plain>[2000] J </plain></SENT>
<SENT sid="4" pm="."><plain>Neurosci </plain></SENT>
<SENT sid="5" pm="."><plain>Res </plain></SENT>
<SENT sid="6" pm="."><plain>60:779-782), however, shows that this peak was also elevated significantly in CSF from patients with <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e> compared to that in controls </plain></SENT>
<SENT sid="7" pm="."><plain>The level in patients with <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e>, where <z:hpo ids='HP_0000726'>dementia</z:hpo> develops in up to 40% of patients, was not elevated significantly compared to that in controls </plain></SENT>
<SENT sid="8" pm="."><plain>To the best of our knowledge, this peak has not yet been identified and we therefore find it appropriate to temporarily designate the name "<z:hpo ids='HP_0000726'>dementia</z:hpo> associated factor" (DAF), although there is as yet no certainty that this substance is specific for these conditions </plain></SENT>
<SENT sid="9" pm="."><plain>Apart from a significantly increased level of glutamine in CSF from patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> compared to that in controls, no other significant difference was found for any other metabolite measured in the patient groups using proton magnetic resonance spectroscopy </plain></SENT>
</text></document>